Fast Growing Stocks With High Insider Ownership

Results

174

14 new

Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.

174 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
	NU New	US$13.84	-3.4%	12.5%	US$66.9b	US$17.98	5.3	20.2%	n/a	Banks
	ALM New	US$14.18	28.2%	244.2%	US$4.1b	US$25.00	114.0	46.0%	n/a	Materials
	HIMX	US$14.61	16.5%	101.0%	US$2.5b	US$30.20	72.2	70.2%	2.5%	Semiconductors
	PGEN	US$7.23	15.3%	306.2%	US$2.6b	US$14.50	30.2	59.3%	n/a	Pharmaceuticals & Biotech
	DAVE	US$317.93	-14.7%	73.7%	US$4.1b	US$421.73	18.2	22.2%	n/a	Diversified Financials
	KRMN	US$58.23	20.9%	27.2%	US$7.7b	US$90.20	207.6	55.7%	n/a	Capital Goods
	APP	US$346.80	-12.4%	-23.9%	US$116.1b	US$560.83	26.3	20.7%	n/a	Media
	CBRS	US$226.73	14.1%	n/a	US$51.4b	US$292.00	525.5	73.7%	n/a	Semiconductors
	UPST	US$31.09	13.3%	-54.8%	US$3.0b	US$40.60	50.1	66.5%	n/a	Diversified Financials
	CG	US$47.79	3.8%	-23.2%	US$16.9b	US$57.82	46.4	20.5%	2.9%	Diversified Financials
	UXIN	US$1.28	-7.9%	-66.5%	US$281.6m	US$4.00	0.5	69.4%	n/a	Retail
	SMCI	US$31.13	9.6%	-30.2%	US$20.1b	US$37.81	16.1	22.4%	n/a	Tech
	IREN	US$41.23	12.0%	123.5%	US$14.7b	US$81.73	93.2	40.2%	n/a	Software
	EROC	US$10.59	3.2%	n/a	US$2.9b	US$22.63	2.7	56.3%	n/a	Capital Goods
	HNGE	US$89.33	19.6%	57.6%	US$7.2b	US$101.67	67.2	35.1%	n/a	Healthcare
	ALOY	US$12.27	39.7%	87.6%	US$844.0m	US$17.00	560.4	77.0%	n/a	Materials
	TEM	US$52.05	18.6%	-14.5%	US$8.3b	US$62.64	6.6	45.0%	n/a	Pharmaceuticals & Biotech
	FIGR	US$28.62	14.9%	n/a	US$6.3b	US$51.14	58.7	53.8%	n/a	Diversified Financials
	ONON	US$37.55	3.6%	-17.8%	US$12.4b	US$52.53	40.1	23.2%	n/a	Consumer Durables
	LSF	US$4.34	4.3%	-27.1%	US$47.8m	US$5.17	0.9	115.9%	n/a	Food, Beverage & Tobacco
	INMB New	US$2.09	19.1%	-18.6%	US$55.4m	US$7.00	2.7	49.3%	n/a	Pharmaceuticals & Biotech
	YSS	US$11.41	-22.5%	n/a	US$1.5b	US$33.44	3.8	103.3%	n/a	Capital Goods
	KVHI	US$8.03	-13.3%	52.1%	US$156.6m	n/a	1.3	167.0%	n/a	Tech
	FRMM	US$6.02	16.7%	-79.9%	US$79.5m	US$9.50	8.5	127.7%	n/a	Pharmaceuticals & Biotech

Page 1 of 5